Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Bristol-Myers Squibb Company (BMY)

66.54   0.52 (0.79%) 01-17 17:37
Open: 66.02 Pre. Close: 66.02
High: 66.86 Low: 65.54
Volume: 10,793,049 Market Cap: 150,364M
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products in hematology, oncology, cardiovascular, and immunology therapeutic classes. The company's products include Opdivo for anti-cancer indications; Eliquis, an oral inhibitor targeted at stroke prevention in adult patients with non-valvular atrial fibrillation, and the prevention and treatment of venous thromboembolic disorders; and Orencia for adult patients with active RA and prostate-specific antigen, as well as reducing signs and symptoms in pediatric patients with active polyarticular juvenile idiopathic arthritis. It also provides Sprycel, a tyrosine kinase inhibitor for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy, a monoclonal antibody for the treatment of patients with unresectable or metastatic melanoma; Empliciti, a humanized monoclonal antibody for the treatment of multiple myeloma; and Baraclude, an oral antiviral agent for the treatment of chronic hepatitis B. In addition, it offers Reyataz, a protease inhibitor to treat human immunodeficiency virus (HIV); Sustiva franchise, a non-nucleoside reverse transcriptase inhibitor for the treatment of HIV; and Daklinza NS5A replication complex inhibitor, Sunvepra NS3 protease inhibitor, and Beclabuvir NS5B inhibitor. It sells products to wholesalers, retail pharmacies, hospitals, government entities, and medical profession. The company has collaboration agreements with Pfizer, Otsuka, Ono, Nektar, GRYT Health, Ubiquigent Limited, and Sensyne Health plc; clinical collaboration agreement with NeoImmuneTech, Inc.; partnership with Astrazeneca Plc.; and a discovery collaboration with Insitro, Inc. The company was formerly known as Bristol-Myers Company and changed its name to Bristol-Myers Squibb Company in 1989. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 66.942 - 67.191 67.191 - 67.39
Low: 64.877 - 65.191 65.191 - 65.443
Close: 66.068 - 66.553 66.553 - 66.944

Technical analysis

as of: 2021-01-15 4:38:16 PM
Stoxline posted a BUY today, same as yesterday. Upward movement continues.
Target: Six months: 78.09     One year: 91.21
Support: Support1: 62.57    Support2: 59.92
Resistance: Resistance1: 66.86    Resistance2: 78.09
Pivot: 62.99
Moving Average: MA(5): 65.54     MA(20): 62.75
MA(100): 61.33     MA(250): 60.54
MACD: MACD(12,26):     Signal(9): 0.48
Stochastic oscillator: %K(14,3): 87.38     %D(3): 85.18
RSI: RSI(14): 70.99
52-week: High: 68.34  Low: 45.76  Change(%): -1.3
Average Vol(K): 3-Month: 1058170  10-Days: 1235639

Price, moving averages and Bollinger Bands

Price and moving averages has closed above its Short term moving average. Short term moving average is currently above mid-term; AND above long term moving averages. From the relationship between price and moving averages; we can see that: This stock is BULLISH in short-term; and BULLISH in mid-long term.
BMY has closed below upper band by 2.8%. Bollinger Bands are 64.1% wider than normal. The large width of the bands suggest high volatility as compared to BMY's normal range. The bands have been in this wide range for 1 bars. This is a sign that the current trend might continue.

Headline News

Fri, 15 Jan 2021
Bristol-Myers Squibb (BMY) Gains As Market Dips: What You Should Know - Yahoo Finance

Fri, 15 Jan 2021
Is Bristol-Myers Squibb (BMY) Stock a Buy For 2021? - Yahoo Finance

Fri, 15 Jan 2021
Bristol Myers Provides Long-Term Guidance: Stock Could Be Poised To Breakout - Seeking Alpha

Tue, 12 Jan 2021
Bristol-Myers Squibb (BMY) Outpaces Stock Market Gains: What You Should Know - Yahoo Finance

Tue, 12 Jan 2021
Bristol-Myers Squibb Could Finally Make Its Move - RealMoney

Mon, 11 Jan 2021
Bristol-Myers Squibb Company's (BMY) CEO Giovanni Caforio Presents at 39th Annual JPMorgan Virtual Healthcare Conference - (Transcript) - Seeking Alpha

Financial Analysis

Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing.
Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs.
Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry.
Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not.
Price to Book Value: Outperform Discounted cash flow: Outperform
Return on Assets: Neutral Price to Earnings: Outperform
Return on Equity: Neutral Debt to Equity: Outperform
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NYSE
Sector:  Healthcare
Industry:  Drug Manufacturers General
Shares Out. (M) 2,260
Shares Float (M) 2,230
% Held by Insiders 0.08
% Held by Institutions 75.79
Shares Short (K) 15,410
Shares Short P. Month (K) 16,140

Stock Financials

EPS -0.020
EPS Est This Year 3.000
EPS Est Next Year 3.230
Book Value (p.s.) 22.200
Profit Margin -0.11
Operating Margin 20.04
Return on Assets (ttm) 5.4
Return on Equity (ttm) -0.1
Qtrly Rev. Growth 75.5
Gross Profit (p.s.) 8.376
Sales Per Share 17.434
EBITDA (p.s.) 7.442
Qtrly Earnings Growth 38.40
Operating Cash Flow (M) 12,420
Levered Free Cash Flow (M) 14,970

Stock Valuations

PE Ratio -3327.00
PEG Ratio 0.82
Price to Book value 3.00
Price to Sales 3.82
Price to Cash Flow 12.11

Stock Dividends

Dividend 1.800
Forward Dividend 1.960
Dividend Yield 0.03
Dividend Pay Date 2021-01-31
Ex-Dividend Date 2020-12-30
7 Binary Options
Your Ad Here
Stock Chart
Stoxline Lite
Stoxline Pro
Option Calculator
(c) 2006-2020 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.